lucarista-shutterstock-com
lucarista / Shutterstock.com
29 April 2015Big Pharma

English High Court invalidates Novartis’s Alzheimer’s patch patent

The English High Court has ruled that a patent covering Novartis’s transdermal patch treatment for Alzheimer’s disease, Exelon (rivastigmine), is invalid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk